Latest Pseudomonas infection Stories
Researchers at National Jewish Health have discovered a promising strategy for destroying the molecular scaffolding that can make Pseudomonas bacterial infections extremely difficult to treat in cystic fibrosis patients, wearers of contact lenses, and burn victims.
New clues about the most common cause of persistent and fatal lung infections in cystic fibrosis patients may lead to preventive treatments.
Transave, a biopharmaceutical company, has secured a $12.5 million venture loan from CIT Healthcare and Compass Horizon Funding Company, an affiliate of Horizon Technology Finance Management.
MONMOUTH JUNCTION, N.J., Oct.
Canadian medical scientists say they have found a new treatment for severe lung infections caused by cystic fibrosis.
Aradigm has announced positive results from an open-label, two week efficacy and safety study of its once daily inhaled liposomal ciprofloxacin in patients with cystic fibrosis.
Mpex Pharmaceuticals has initiated a Phase II clinical study with MP-376 for the treatment of pulmonary infections due to Pseudomonas aeruginosa and other bacteria in patients with cystic fibrosis.
Gilead Sciences has announced positive results from an interim analysis of 12-month data from its open-label, Phase III AIR-CF3 study of aztreonam lysine for inhalation, an investigational therapy in development for the treatment of people with cystic fibrosis who have pulmonary Pseudomonas aeruginosa.
New U of T research holds promise for developing innovative therapies against cystic fibrosis and may also serve as a model for future therapies against the HIV virus.
Cells sent to fight infections in the lungs of cystic fibrosis patients actually enhance the development of permanent bacterial infections, according to researchers at National Jewish Medical and Research Center.